December 2022

Elixirgen Therapeutics Appoints Jeffrey L. Cleland, Ph.D., to Board of Directors

Press Release /

BALTIMORE, Dec. 21, 2022 — Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its controllable self-replicating RNA (c-srRNA) platform, today announced the appointment of Jeffrey L. Cleland, Ph.D., to the Board of Directors to support the advancement of its technology in developing therapies for a broad […]

Elixirgen Therapeutics Appoints Jeffrey L. Cleland, Ph.D., to Board of Directors Read More »

Elixirgen Therapeutics Presents New Clinical Data Demonstrating Ex Vivo Telomere Elongation with EXG-34217 in Dyskeratosis Congenita at the 64th ASH Annual Meeting

Press Release /

Elixirgen Therapeutics Presents New Clinical Data Demonstrating Ex Vivo Telomere Elongation with EXG-34217 in Dyskeratosis Congenita at the 64th ASH Annual Meeting Treatment with EXG-34217 increased the telomere length of CD34+ cells by 1.24-fold ex vivo Telomere flow-FISH study suggests the potential emergence of a cell population with longer telomeres in vivo No acute or

Elixirgen Therapeutics Presents New Clinical Data Demonstrating Ex Vivo Telomere Elongation with EXG-34217 in Dyskeratosis Congenita at the 64th ASH Annual Meeting Read More »